These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 19963033)

  • 1. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
    Smeesters PR; Dramaix M; Van Melderen L
    Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development.
    Smeesters PR; Mardulyn P; Vergison A; Leplae R; Van Melderen L
    Vaccine; 2008 Oct; 26(46):5835-42. PubMed ID: 18789365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
    Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
    Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
    Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
    BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemic of group A Streptococcus M/emm59 causing invasive disease in Canada.
    Tyrrell GJ; Lovgren M; St Jean T; Hoang L; Patrick DM; Horsman G; Van Caeseele P; Sieswerda LE; McGeer A; Laurence RA; Bourgault AM; Low DE
    Clin Infect Dis; 2010 Dec; 51(11):1290-7. PubMed ID: 21034198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunity to group a streptococcal M proteins: forging a single-edged sword.
    Madoff LC
    Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
    [No Abstract]   [Full Text] [Related]  

  • 7. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
    Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
    Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seven-year surveillance of north american pediatric group a streptococcal pharyngitis isolates.
    Shulman ST; Tanz RR; Dale JB; Beall B; Kabat W; Kabat K; Cederlund E; Patel D; Rippe J; Li Z; Sakota V;
    Clin Infect Dis; 2009 Jul; 49(1):78-84. PubMed ID: 19480575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biology of Group A
    Brahmadathan NK
    Indian J Med Microbiol; 2017; 35(2):176-183. PubMed ID: 28681803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Group A streptococcal infections: trend and strain emm typing in an area of central Italy, 1985-2002.
    Mencarelli M; Corbisiero R; Padula MG; Galgani I; Stolzuoli L; Cellesi C
    Epidemiol Infect; 2005 Dec; 133(6):1107-11. PubMed ID: 16274508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The quest for GAS vaccine.
    Pandey M; Good MF
    Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
    [No Abstract]   [Full Text] [Related]  

  • 12. Group A streptococcus epidemiology and vaccine implications.
    Cohen-Poradosu R; Kasper DL
    Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050
    [No Abstract]   [Full Text] [Related]  

  • 13. M protein gene (emm type) analysis of group A beta-hemolytic streptococci from Ethiopia reveals unique patterns.
    Tewodros W; Kronvall G
    J Clin Microbiol; 2005 Sep; 43(9):4369-76. PubMed ID: 16145079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverage.
    Engel ME; Muhamed B; Whitelaw AC; Musvosvi M; Mayosi BM; Dale JB
    Pediatr Infect Dis J; 2014 Feb; 33(2):208-10. PubMed ID: 23934204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Distribution of emm genotypes and antibiotic susceptibility of Streptococcus pyogenes strains: analogy with the vaccine in development].
    Arslan U; Oryaşın E; Eskin Z; Türk Dağı H; Fındık D; Tuncer I; Bozdoğan B
    Mikrobiyol Bul; 2013 Apr; 47(2):318-23. PubMed ID: 23621731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
    Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
    Good MF; Pandey M; Batzloff MR; Tyrrell GJ
    Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of emm typing and ribotyping with three restriction enzymes to characterize clinical isolates of Streptococcus pyogenes.
    Doktor SZ; Beyer JM; Flamm RK; Shortridge VD
    J Clin Microbiol; 2005 Jan; 43(1):150-5. PubMed ID: 15634964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of emm types and superantigens of Streptococcus pyogenes isolates from children during two sampling periods.
    Ma Y; Yang Y; Huang M; Wang Y; Chen Y; Deng L; Yu S; Deng Q; Zhang H; Wang C; Liu L; Shen X
    Epidemiol Infect; 2009 Oct; 137(10):1414-9. PubMed ID: 19243651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Streptococcus pyogenes emm and T types within a decade, 1996-2005: implications for epidemiology and future vaccines.
    Nir-Paz R; Korenman Z; Ron M; Michael-Gayego A; Cohen-Poradosu R; Valinsky L; Beall B; Moses AE
    Epidemiol Infect; 2010 Jan; 138(1):53-60. PubMed ID: 19480723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.